Inflammatory mediators hold the key to dendritic cell suppression and tumor progression

Current Medicinal Chemistry

Volumn 18, Issue 36, 2011, Pages 5507-5518

  Sheng, K C ^a,b   Wright, M D ^c   Apostolopoulos, V ^a  

^a BURNET INSTITUTE   (Australia)

^b AGENCY FOR SCIENCE   (Singapore)

^c MONASH UNIVERSITY   (Australia)

Author keywords

Cancer; Dendritic cells; Inflammation; Inflammatory mediators; Tumor

Indexed keywords

COLONY STIMULATING FACTOR 1; GANGLIOSIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 8; LACTIC ACID; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL FUNCTION; CELL GROWTH; CELL STIMULATION; CELL SURVIVAL; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; INFLAMMATION; NONHUMAN; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 84055183917     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711798347207     Document Type: Article

References (250)

1. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev, 2008, 18, 11-18. (Pubitemid 351694442)
2. Ostrand-Rosenberg S.; Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol, 2009, 182, 4499-4506.
3. Coussens L.M.; Werb Z. Inflammation and cancer. Nature, 2002, 420, 860-867. (Pubitemid 36019639)
4. Balkwill F.; Charles K.A.; Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell, 2005, 7, 211-217. (Pubitemid 40568680)
5. Luster A.D.; Alon R.; von Andrian U.H. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol, 2005, 6, 1182-1190. (Pubitemid 43045626)
6. Lin W.W.; Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest, 2007, 117, 1175-1183. (Pubitemid 46718402)
7. Tanno T.; Matsui W. Development and Maintenance of Cancer Stem Cells under Chronic Inflammation. J Nippon Med Sch, 2011, 78, 138-145.
8. Kuper H.; Adami H.O.; Trichopoulos D. Infections as a major preventable cause of human cancer. J Intern Med, 2000, 248, 171-183. (Pubitemid 33702479)
9. Mantovani A.; Allavena P.; Sica A.; Balkwill F. Cancer-related inflammation. Nature, 2008, 454, 436-444.
10. Smyth M.J.; Dunn G.P.; Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol, 2006, 90, 1-50. (Pubitemid 43765795)
11. van den Broek M.; von Boehmer L.; Knuth A. Developments in cancer immunotherapy. Dig Dis, 2010, 28, 51-56.
12. Koebel C.M.; Vermi W.; Swann J.B.; Zerafa N.; Rodig S.J.; Old L.J.; Smyth M.J.; Schreiber R.D. Adaptive immunity maintains occult cancer in an equilibrium state. Nature, 2007, 450, 903-907. (Pubitemid 350231320)
13. Muller-Hubenthal B.; Azemar M.; Lorenzen D.; Huber M.; Freudenberg M.A.; Galanos C.; Unger C.; Hildenbrand B. Tumour Biology: tumourassociated inflammation versus antitumor immunity. Anticancer Res, 2009, 29, 4795-4805.
14. Sheng K.C.; Pietersz G.A.; Wright M.D.; Apostolopoulos V. Dendritic cells: activation and maturation-applications for cancer immunotherapy. Curr Med Chem, 2005, 12, 1783-1800. (Pubitemid 40895000)
15. Hodge D.R.; Hurt E.M.; Farrar W.L. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer, 2005, 41, 2502-2512. (Pubitemid 41540626)
16. Bromberg J.; Wang T.C. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell, 2009, 15, 79-80.
17. Park S.J.; Nakagawa T.; Kitamura H.; Atsumi T.; Kamon H.; Sawa S.; Kamimura D.; Ueda N.; Iwakura Y.; Ishihara K.; Murakami M.; Hirano T. IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol, 2004, 173, 3844-3854. (Pubitemid 39280747)
18. Chomarat P.; Banchereau J.; Davoust J.; Palucka A.K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol, 2000, 1, 510-514.
19. Hegde S.; Pahne J.; Smola-Hess S. Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-kappaB binding activity and CCR7 expression. Faseb J, 2004, 18, 1439-1441. (Pubitemid 39561607)
20. Ratta M.; Fagnoni F.; Curti A.; Vescovini R.; Sansoni P.; Oliviero B.; Fogli M.; Ferri E.; Della Cuna G.R.; Tura S.; Baccarani M.; Lemoli R.M. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood, 2002, 100, 230-237. (Pubitemid 35177452)
21. Kitamura H.; Kamon H.; Sawa S.; Park S.J.; Katunuma N.; Ishihara K.; Murakami M.; Hirano T. IL-6-STAT3 controls intracellular MHC class II alphabeta dimer level through cathepsin S activity in dendritic cells. Immunity, 2005, 23, 491-502. (Pubitemid 41587889)
22. Nefedova Y.; Huang M.; Kusmartsev S.; Bhattacharya R.; Cheng P.; Salup R.; Jove R.; Gabrilovich D. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol, 2004, 172, 464-474. (Pubitemid 38020502)
23. Nefedova Y.; Cheng P.; Gilkes D.; Blaskovich M.; Beg A.A.; Sebti S.M.; Gabrilovich D.I. Activation of dendritic cells via inhibition of Jak2/STAT3 signaling. J Immunol, 2005, 175, 4338-4346. (Pubitemid 41361968)
24. Yu H.; Pardoll D.; Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer, 2009, 9, 798-809.
25. Kortylewski M.; Xin H.; Kujawski M.; Lee H.; Liu Y.; Harris T.; Drake C.; Pardoll D.; Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell, 2009, 15, 114-123.
26. Kortylewski M.; Kujawski M.; Wang T.; Wei S.; Zhang S.; Pilon-Thomas S.; Niu G.; Kay H.; Mule J.; Kerr W.G.; Jove R.; Pardoll D.; Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med, 2005, 11, 1314-1321. (Pubitemid 41752912)
27. Kujawski M.; Kortylewski M.; Lee H.; Herrmann A.; Kay H.; Yu H. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J Clin Invest, 2008, 118, 3367-3377.
28. Cheng P.; Corzo C.A.; Luetteke N.; Yu B.; Nagaraj S.; Bui M.M.; Ortiz M.; Nacken W.; Sorg C.; Vogl T.; Roth J.; Gabrilovich D.I. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med, 2008, 205, 2235-2249.
29. Aggarwal B.B.; Shishodia S.; Sandur S.K.; Pandey M.K.; Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol, 2006, 72, 1605-1621. (Pubitemid 44666739)
30. Grivennikov S.; Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell, 2008, 13, 7-9. (Pubitemid 350309747)
31. Sansone P.; Storci G.; Tavolari S.; Guarnieri T.; Giovannini C.; Taffurelli M.; Ceccarelli C.; Santini D.; Paterini P.; Marcu K.B.; Chieco P.; Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest, 2007, 117, 3988-4002. (Pubitemid 350224108)
32. Neurath M.F.; Finotto S. IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev, 2011, 22, 83-89.
33. Richardsen E.; Sorbye S.W.; Crowe J.P.; Yang J.L.; Busund L.T. Expression of M-CSF and CSF-1R is correlated with histological grade in soft tissue tumors. Anticancer Res, 2009, 29, 3861-3866.
34. Lin E.Y.; Nguyen A.V.; Russell R.G.; Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med, 2001, 193, 727-740.
35. Lin E.Y.; Gouon-Evans V.; Nguyen A.V.; Pollard J.W. The macrophage growth factor CSF-1 in mammary gland development and tumor progression. J Mammary Gland Biol Neoplasia, 2002, 7, 147-162. (Pubitemid 38420772)
36. Serafini P.; Borrello I.; Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol, 2006, 16, 53-65. (Pubitemid 43139709)
37. Menetrier-Caux C.; Thomachot M.C.; Alberti L.; Montmain G.; Blay J.Y. IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res, 2001, 61, 3096-3104. (Pubitemid 32691960)
38. Lo A.S.; Gorak-Stolinska P.; Bachy V.; Ibrahim M.A.; Kemeny D.M.; Maher J. Modulation of dendritic cell differentiation by colony-stimulating factor-1: role of phosphatidylinositol 3'-kinase and delayed caspase activation. J Leukoc Biol, 2007, 82, 1446-1454. (Pubitemid 350276956)
39. Coffelt S.B.; Hughes R.; Lewis C.E. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta, 2009, 1796, 11-18.
40. Mantovani A.; Sica A.; Allavena P.; Garlanda C.; Locati M. Tumorassociated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol, 2009, 70, 325-330.
41. Lamagna C.; Aurrand-Lions M.; Imhof B.A. Dual role of macrophages in tumor growth and angiogenesis. J Leukoc Biol, 2006, 80, 705-713. (Pubitemid 44835885)
42. Curry J.M.; Eubank T.D.; Roberts R.D.; Wang Y.; Pore N.; Maity A.; Marsh C.B. M-CSF signals through the MAPK/ERK pathway via Sp1 to induce VEGF production and induces angiogenesis in vivo. PLoS One, 2008, 3, e3405.
43. Lucas T.; Abraham D.; Aharinejad S. Modulation of tumor associated macrophages in solid tumors. Front Biosci, 2008, 13, 5580-5588.
44. Eubank T.D.; Galloway M.; Montague C.M.; Waldman W.J.; Marsh C.B. MCSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol, 2003, 171, 2637-2643. (Pubitemid 37025577)
45. Lin E.Y.; Li J.F.; Gnatovskiy L.; Deng Y.; Zhu L.; Grzesik D.A.; Qian H.; Xue X.N.; Pollard J.W. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res, 2006, 66, 11238-11246. (Pubitemid 46009952)
46. Schmid M.C.; Varner J.A. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol, 2010, 2010, 201026.
47. Yang L.; Carbone D.P. Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res, 2004, 92, 13-27. (Pubitemid 39458111)
48. Yang L.; DeBusk L.M.; Fukuda K.; Fingleton B.; Green-Jarvis B.; Shyr Y.; Matrisian L.M.; Carbone D.P.; Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell, 2004, 6, 409-421. (Pubitemid 39361441)
49. Toi M.; Inada K.; Suzuki H.; Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat, 1995, 36, 193-204.
50. Verheul H.M.; Hoekman K.; Jorna A.S.; Smit E.F.; Pinedo H.M. Targeting vascular endothelial growth factor blockade: ascites and pleural effusion formation. Oncologist, 2000, 5 Suppl 1, 45-50. (Pubitemid 30225457)
51. Konecny G.E.; Meng Y.G.; Untch M.; Wang H.J.; Bauerfeind I.; Epstein M.; Stieber P.; Vernes J.M.; Gutierrez J.; Hong K.; Beryt M.; Hepp H.; Slamon D.J.; Pegram M.D. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res, 2004, 10, 1706-1716. (Pubitemid 38435562)
52. Gabrilovich D.I.; Chen H.L.; Girgis K.R.; Cunningham H.T.; Meny G.M.; Nadaf S.; Kavanaugh D.; Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med, 1996, 2, 1096-1103. (Pubitemid 26338628)
53. Gabrilovich D.; Ishida T.; Oyama T.; Ran S.; Kravtsov V.; Nadaf S.; Carbone D.P. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood, 1998, 92, 4150-4166. (Pubitemid 28544331)
54. Xue Y.; Chen F.; Zhang D.; Lim S.; Cao Y. Tumor-derived VEGF modulates hematopoiesis. J Angiogenes Res, 2009, 1, 9.
55. Dikov M.M.; Ohm J.E.; Ray N.; Tchekneva E.E.; Burlison J.; Moghanaki D.; Nadaf S.; Carbone D.P. Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol, 2005, 174, 215-222. (Pubitemid 40007407)
56. Dineen S.P.; Lynn K.D.; Holloway S.E.; Miller A.F.; Sullivan J.P.; Shames D.S.; Beck A.W.; Barnett C.C.; Fleming J.B.; Brekken R.A. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res, 2008, 68, 4340-4346.
57. Johnson B.; Osada T.; Clay T.; Lyerly H.; Morse M. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr Mol Med, 2009, 9, 702-707.
58. Waldner M.J.; Wirtz S.; Jefremow A.; Warntjen M.; Neufert C.; Atreya R.; Becker C.; Weigmann B.; Vieth M.; Rose-John S.; Neurath M.F. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med, 2010, 207, 2855-2868.
59. Liu Y.; Cox S.R.; Morita T.; Kourembanas S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ Res, 1995, 77, 638-643.
60. Veikkola T.; Karkkainen M.; Claesson-Welsh L.; Alitalo K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res, 2000, 60, 203-212. (Pubitemid 30070735)
61. Wei D.; Le X.; Zheng L.; Wang L.; Frey J.A.; Gao A.C.; Peng Z.; Huang S.; Xiong H.Q.; Abbruzzese J.L.; Xie K. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene, 2003, 22, 319-329. (Pubitemid 36194328)
62. Wei L.H.; Kuo M.L.; Chen C.A.; Chou C.H.; Lai K.B.; Lee C.N.; Hsieh C.Y. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene, 2003, 22, 1517-1527.
63. Bartoli M.; Platt D.; Lemtalsi T.; Gu X.; Brooks S.E.; Marrero M.B.; Caldwell R.B. VEGF differentially activates STAT3 in microvascular endothelial cells. Faseb J, 2003, 17, 1562-1564.
64. Gottfried E.; Kreutz M.; Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev, 2008, 19, 65-77. (Pubitemid 351200062)
65. Wang F.Q.; So J.; Reierstad S.; Fishman D.A. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer, 2006, 118, 879-888. (Pubitemid 43157663)
66. Bachelder R.E.; Wendt M.A.; Mercurio A.M. Vascular endothelial growth factor promotes breast carcinoma invasion in an autocrine manner by regulating the chemokine receptor CXCR4. Cancer Res, 2002, 62, 7203-7206. (Pubitemid 36025239)
67. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev, 2006, 25, 435-457. (Pubitemid 44922360)
68. Pardali K.; Moustakas A. Actions of TGF-beta as tumor suppressor and prometastatic factor in human cancer. Biochim Biophys Acta, 2007, 1775, 21-62. (Pubitemid 44881193)
69. Derynck R.; Akhurst R.J.; Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 2001, 29, 117-129. (Pubitemid 32952643)
70. Yang L.; Pang Y.; Moses H.L. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol, 2010, 31, 220-227.
71. Inman G.J. Switching TGFbeta from a tumor suppressor to a tumor promoter. Curr Opin Genet Dev, 2011, 21, 93-99.
72. Yang J.; Wahdan-Alaswad R.; Danielpour D. Critical role of Smad2 in tumor suppression and transforming growth factor-beta-induced apoptosis of prostate epithelial cells. Cancer Res, 2009, 69, 2185-2190.
73. Levy L.; Hill C.S. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev, 2006, 17, 41-58. (Pubitemid 43117515)
74. Bierie B.; Moses H.L. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev, 2010, 21, 49-59.
75. Yang G.; Yang X. Smad4-mediated TGF-beta signaling in tumorigenesis. Int J Biol Sci, 2010, 6, 1-8.
76. Kang Y.; He W.; Tulley S.; Gupta G.P.; Serganova I.; Chen C.R.; Manova-Todorova K.; Blasberg R.; Gerald W.L.; Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A, 2005, 102, 13909-13914. (Pubitemid 41377677)
77. Meulmeester E.; Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol, 2011, 223, 205-218.
78. Nam E.H.; Park S.R.; Kim P.H. TGF-beta1 induces mouse dendritic cells to express VEGF and its receptor (Flt-1) under hypoxic conditions. Exp Mol Med, 2010, 42, 606-613.
79. Ohtani T.; Mizuashi M.; Nakagawa S.; Sasaki Y.; Fujimura T.; Okuyama R.; Aiba S. TGF-beta1 dampens the susceptibility of dendritic cells to environmental stimulation, leading to the requirement for danger signals for activation. Immunology, 2009, 126, 485-499.
80. Liu Q.; Zhang C.; Sun A.; Zheng Y.; Wang L.; Cao X. Tumor-educated CD11bhighIalow regulatory dendritic cells suppress T cell response through arginase I. J Immunol, 2009, 182, 6207-6216.
81. Ghiringhelli F.; Puig P.E.; Roux S.; Parcellier A.; Schmitt E.; Solary E.; Kroemer G.; Martin F.; Chauffert B.; Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med, 2005, 202, 919-929. (Pubitemid 41396892)
82. Dumitriu I.E.; Dunbar D.R.; Howie S.E.; Sethi T.; Gregory C.D. Human dendritic cells produce TGF-beta 1 under the influence of lung carcinoma cells and prime the differentiation of CD4+CD25+Foxp3+ regulatory T cells. J Immunol, 2009, 182, 2795-2807.
83. Mantovani A.; Savino B.; Locati M.; Zammataro L.; Allavena P.; Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev, 2010, 21, 27-39.
84. Ghadjar P.; Rubie C.; Aebersold D.M.; Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer, 2009, 125, 741-745.
85. Beider K.; Abraham M.; Begin M.; Wald H.; Weiss I.D.; Wald O.; Pikarsky E.; Abramovitch R.; Zeira E.; Galun E.; Nagler A.; Peled A. Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One, 2009, 4, e5125.
86. Bell D.; Chomarat P.; Broyles D.; Netto G.; Harb G.M.; Lebecque S.; Valladeau J.; Davoust J.; Palucka K.A.; Banchereau J. In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med, 1999, 190, 1417-1426.
87. Waugh D.J.; Wilson C.; Seaton A.; Maxwell P.J. Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci, 2008, 13, 4595-4604. (Pubitemid 351589184)
88. Feijoo E.; Alfaro C.; Mazzolini G.; Serra P.; Penuelas I.; Arina A.; Huarte E.; Tirapu I.; Palencia B.; Murillo O.; Ruiz J.; Sangro B.; Richter J.A.; Prieto J.; Melero I. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. Int J Cancer, 2005, 116, 275-281. (Pubitemid 40967265)
89. Murphy C.; McGurk M.; Pettigrew J.; Santinelli A.; Mazzucchelli R.; Johnston P.G.; Montironi R.; Waugh D.J. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res, 2005, 11, 4117-4127. (Pubitemid 40791576)
90. Chavey C.; Bibeau F.; Gourgou-Bourgade S.; Burlinchon S.; Boissiere F.; Laune D.; Roques S.; Lazennec G. Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res, 2007, 9, R15.
91. Shahzad A.; Knapp M.; Lang I.; Kohler G. Interleukin 8 (IL-8) -a universal biomarker? Int Arch Med, 2010, 3, 11.
92. Yuan A.; Chen J.J.; Yao P.L.; Yang P.C. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci, 2005, 10, 853-865.
93. Schraufstatter I.U.; Trieu K.; Zhao M.; Rose D.M.; Terkeltaub R.A.; Burger M. IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor. J Immunol, 2003, 171, 6714-6722. (Pubitemid 37532104)
94. Petreaca M.L.; Yao M.; Liu Y.; Defea K.; Martins-Green M. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell, 2007, 18, 5014-5023. (Pubitemid 350246701)
95. Bogdan C.; Rollinghoff M.; Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr Opin Immunol, 2000, 12, 64-76. (Pubitemid 30093452)
96. Kamp D.W.; Shacter E.; Weitzman S.A. Chronic inflammation and cancer: the role of the mitochondria. Oncology (Williston Park), 2011, 25, 400-410, 413.
97. Bedard K.; Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev, 2007, 87, 245-313. (Pubitemid 46209993)
98. Matsuzawa A.; Saegusa K.; Noguchi T.; Sadamitsu C.; Nishitoh H.; Nagai S.; Koyasu S.; Matsumoto K.; Takeda K.; Ichijo H. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat Immunol, 2005, 6, 587-592. (Pubitemid 41710729)
99. Lo Y.Y.; Wong J.M.; Cruz T.F. Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. J Biol Chem, 1996, 271, 15703-15707. (Pubitemid 26225348)
100. Ishikawa K.; Takenaga K.; Akimoto M.; Koshikawa N.; Yamaguchi A.; Imanishi H.; Nakada K.; Honma Y.; Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science, 2008, 320, 661-664. (Pubitemid 351928347)
101. Schumacker P.T. Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell, 2006, 10, 175-176. (Pubitemid 44311072)
102. Ullman T.A.; Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology, 2011, 140, 1807-1816.
103. Chiarugi P.; Pani G.; Giannoni E.; Taddei L.; Colavitti R.; Raugei G.; Symons M.; Borrello S.; Galeotti T.; Ramponi G. Reactive oxygen species as essential mediators of cell adhesion: the oxidative inhibition of a FAK tyrosine phosphatase is required for cell adhesion. J Cell Biol, 2003, 161, 933-944. (Pubitemid 36718426)
104. Thannickal V.J.; Fanburg B.L. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol, 2000, 279, L1005-1028. (Pubitemid 32009487)
105. Boonstra J.; Post J.A. Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells. Gene, 2004, 337, 1-13. (Pubitemid 38970100)
106. Hildeman D.A.; Mitchell T.; Aronow B.; Wojciechowski S.; Kappler J.; Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc Natl Acad Sci U S A, 2003, 100, 15035-15040. (Pubitemid 37518012)
107. Wu R.F.; Terada L.S. Oxidative modification of protein tyrosine phosphatases. Sci STKE, 2006, 2006, pl2.
108. Carreau A.; Kieda C.; Grillon C. Nitric oxide modulates the expression of endothelial cell adhesion molecules involved in angiogenesis and leukocyte recruitment. Exp Cell Res, 2010.
109. Ziche M.; Morbidelli L. Molecular regulation of tumour angiogenesis by nitric oxide. Eur Cytokine Netw, 2009, 20, 164-170.
110. Wu W.S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev, 2006, 25, 695-705.
111. DeYulia G.J., Jr.; Carcamo J.M.; Borquez-Ojeda O.; Shelton C.C.; Golde D.W. Hydrogen peroxide generated extracellularly by receptor-ligand interaction facilitates cell signaling. Proc Natl Acad Sci U S A, 2005, 102, 5044-5049.
112. Gloire G.; Legrand-Poels S.; Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol, 2006, 72, 1493-1505. (Pubitemid 44666727)
113. Remacle J.; Raes M.; Toussaint O.; Renard P.; Rao G. Low levels of reactive oxygen species as modulators of cell function. Mutat Res, 1995, 316, 103-122.
114. Kantengwa S.; Jornot L.; Devenoges C.; Nicod L.P. Superoxide anions induce the maturation of human dendritic cells. Am J Respir Crit Care Med, 2003, 167, 431-437. (Pubitemid 36216428)
115. Perrotta C.; Falcone S.; Capobianco A.; Camporeale A.; Sciorati C.; De Palma C.; Pisconti A.; Rovere-Querini P.; Bellone M.; Manfredi A.A.; Clementi E. Nitric oxide confers therapeutic activity to dendritic cells in a mouse model of melanoma. Cancer Res, 2004, 64, 3767-3771. (Pubitemid 38697285)
116. Huang J.; Tatsumi T.; Pizzoferrato E.; Vujanovic N.; Storkus W.J. Nitric oxide sensitizes tumor cells to dendritic cell-mediated apoptosis, uptake, and cross-presentation. Cancer Res, 2005, 65, 8461-8470. (Pubitemid 41330614)
117. Gabrilovich D.I.; Bronte V.; Chen S.H.; Colombo M.P.; Ochoa A.; Ostrand-Rosenberg S.; Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res, 2007, 67, 425; author reply 426. (Pubitemid 46142802)
118. Gabrilovich D.I.; Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol, 2009, 9, 162-174.
119. Nagaraj S.; Gabrilovich D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res, 2008, 68, 2561-2563. (Pubitemid 351556251)
120. Verhasselt V.; Goldman M.; Willems F. Oxidative stress up-regulates IL-8 and TNF-alpha synthesis by human dendritic cells. Eur J Immunol, 1998, 28, 3886-3890. (Pubitemid 28510800)
121. Corzo C.A.; Cotter M.J.; Cheng P.; Cheng F.; Kusmartsev S.; Sotomayor E.; Padhya T.; McCaffrey T.V.; McCaffrey J.C.; Gabrilovich D.I. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J Immunol, 2009, 182, 5693-5701.
122. Serafini P.; Carbley R.; Noonan K.A.; Tan G.; Bronte V.; Borrello I. Highdose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res, 2004, 64, 6337-6343. (Pubitemid 39129439)
123. Parmiani G.; Castelli C.; Pilla L.; Santinami M.; Colombo M.P.; Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol, 2007, 18, 226-232. (Pubitemid 46323086)
124. Sheng K.C.; Pietersz G.A.; Tang C.K.; Ramsland P.A.; Apostolopoulos V. Reactive oxygen species level defines two functionally distinctive stages of inflammatory dendritic cell development from mouse bone marrow. J Immunol, 2010, 184, 2863-2872.
125. Wang M.T.; Honn K.V.; Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev, 2007, 26, 525-534. (Pubitemid 350115125)
126. Gualde N.; Harizi H. Prostanoids and their receptors that modulate dendritic cell-mediated immunity. Immunol Cell Biol, 2004, 82, 353-360. (Pubitemid 39141757)
127. Wang D.; Dubois R.N. Prostaglandins and cancer. Gut, 2006, 55, 115-122. (Pubitemid 41820645)
128. Wang D.; Buchanan F.G.; Wang H.; Dey S.K.; DuBois R.N. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogenactivated protein kinase cascade. Cancer Res, 2005, 65, 1822-1829. (Pubitemid 40478610)
129. Sheng H.; Shao J.; Morrow J.D.; Beauchamp R.D.; DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res, 1998, 58, 362-366. (Pubitemid 28047080)
130. Poligone B.; Baldwin A.S. Positive and negative regulation of NF-kappaB by COX-2: roles of different prostaglandins. J Biol Chem, 2001, 276, 38658-38664.
131. Kage K.; Fujita N.; Oh-hara T.; Ogata E.; Fujita T.; Tsuruo T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem Biophys Res Commun, 1999, 254, 259-263. (Pubitemid 29292050)
132. Harizi H.; Gualde N. Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol, 2006, 3, 271-277.
133. Tilley S.L.; Coffman T.M.; Koller B.H. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest, 2001, 108, 15-23. (Pubitemid 32634916)
134. Dassesse T.; de Leval X.; de Leval L.; Pirotte B.; Castronovo V.; Waltregny D. Activation of the thromboxane A2 pathway in human prostate cancer correlates with tumor Gleason score and pathologic stage. Eur Urol, 2006, 50, 1021-1031; discussion 1031. (Pubitemid 44486476)
135. Pan M.R.; Hou M.F.; Chang H.C.; Hung W.C. Cyclooxygenase-2 upregulates CCR7 via EP2/EP4 receptor signaling pathways to enhance lymphatic invasion of breast cancer cells. J Biol Chem, 2008, 283, 11155-11163.
136. Zeidler R.; Csanady M.; Gires O.; Lang S.; Schmitt B.; Wollenberg B. Tumor cell-derived prostaglandin E2 inhibits monocyte function by interfering with CCR5 and Mac-1. Faseb J, 2000, 14, 661-668. (Pubitemid 30198565)
137. Munn D.H.; Sharma M.D.; Lee J.R.; Jhaver K.G.; Johnson T.S.; Keskin D.B.; Marshall B.; Chandler P.; Antonia S.J.; Burgess R.; Slingluff C.L., Jr.; Mellor A.L. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science, 2002, 297, 1867-1870. (Pubitemid 35024345)
138. Chemnitz J.M.; Driesen J.; Classen S.; Riley J.L.; Debey S.; Beyer M.; Popov A.; Zander T.; Schultze J.L. Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res, 2006, 66, 1114-1122. (Pubitemid 43165980)
139. Yen J.H.; Khayrullina T.; Ganea D. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood, 2008, 111, 260-270.
140. Jonuleit H.; Kuhn U.; Muller G.; Steinbrink K.; Paragnik L.; Schmitt E.; Knop J.; Enk A.H. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol, 1997, 27, 3135-3142. (Pubitemid 28018007)
141. Harizi H.; Juzan M.; Pitard V.; Moreau J.F.; Gualde N. Cyclooxygenase-2-issued prostaglandin e(2) enhances the production of endogenous IL-10, which down-regulates dendritic cell functions. J Immunol, 2002, 168, 2255-2263. (Pubitemid 34171825)
142. Hilkens C.M.; Snijders A.; Snijdewint F.G.; Wierenga E.A.; Kapsenberg M.L. Modulation of T-cell cytokine secretion by accessory cell-derived products. Eur Respir J Suppl, 1996, 22, 90s-94s.
143. Kalinski P.; Vieira P.L.; Schuitemaker J.H.; de Jong E.C.; Kapsenberg M.L. Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood, 2001, 97, 3466-3469.
144. Ahmadi M.; Emery D.C.; Morgan D.J. Prevention of both direct and crosspriming of antitumor CD8+ T-cell responses following overproduction of prostaglandin E2 by tumor cells in vivo. Cancer Res, 2008, 68, 7520-7529.
145. Sinha P.; Clements V.K.; Fulton A.M.; Ostrand-Rosenberg S. Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells. Cancer Res, 2007, 67, 4507-4513. (Pubitemid 46815102)
146. Li Z.; Rich J.N. Hypoxia and hypoxia inducible factors in cancer stem cell maintenance. Curr Top Microbiol Immunol, 2010, 345, 21-30.
147. Semenza G.L. Tumor metabolism: cancer cells give and take lactate. J Clin Invest, 2008, 118, 3835-3837.
148. Sonveaux P.; Vegran F.; Schroeder T.; Wergin M.C.; Verrax J.; Rabbani Z.N.; De Saedeleer C.J.; Kennedy K.M.; Diepart C.; Jordan B.F.; Kelley M.J.; Gallez B.; Wahl M.L.; Feron O.; Dewhirst M.W. Targeting lactatefueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest, 2008, 118, 3930-3942.
149. Walenta S.; Schroeder T.; Mueller-Klieser W. Lactate in solid malignant tumors: potential basis of a metabolic classification in clinical oncology. Curr Med Chem, 2004, 11, 2195-2204. (Pubitemid 38967739)
150. Gottfried E.; Kunz-Schughart L.A.; Ebner S.; Mueller-Klieser W.; Hoves S.; Andreesen R.; Mackensen A.; Kreutz M. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood, 2006, 107, 2013-2021. (Pubitemid 43289385)
151. Fischer K.; Hoffmann P.; Voelkl S.; Meidenbauer N.; Ammer J.; Edinger M.; Gottfried E.; Schwarz S.; Rothe G.; Hoves S.; Renner K.; Timischl B.; Mackensen A.; Kunz-Schughart L.; Andreesen R.; Krause S.W.; Kreutz M. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 2007, 109, 3812-3819. (Pubitemid 46641732)
152. Hjelmeland A.B.; Wu Q.; Heddleston J.M.; Choudhary G.S.; MacSwords J.; Lathia J.D.; McLendon R.; Lindner D.; Sloan A.; Rich J.N. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ, 2011, 18, 829-840.
153. Birkle S.; Zeng G.; Gao L.; Yu R.K.; Aubry J. Role of tumor-associated gangliosides in cancer progression. Biochimie, 2003, 85, 455-463. (Pubitemid 36626016)
154. Hakomori S. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res, 1996, 56, 5309-5318. (Pubitemid 27011703)
155. Valentino L.; Moss T.; Olson E.; Wang H.J.; Elashoff R.; Ladisch S. Shed tumor gangliosides and progression of human neuroblastoma. Blood, 1990, 75, 1564-1567. (Pubitemid 20114898)
156. Alessandri G.; Cornaglia-Ferraris P.; Gullino P.M. Angiogenic and angiostatic microenvironment in tumors-role of gangliosides. Acta Oncol, 1997, 36, 383-387. (Pubitemid 27298557)
157. McKallip R.; Li R.; Ladisch S. Tumor gangliosides inhibit the tumor-specific immune response. J Immunol, 1999, 163, 3718-3726. (Pubitemid 29450894)
158. Li R.; Villacreses N.; Ladisch S. Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res, 1995, 55, 211-214.
159. Crespo F.A.; Sun X.; Cripps J.G.; Fernandez-Botran R. The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J Leukoc Biol, 2006, 79, 586-595. (Pubitemid 44831235)
160. Biswas S.; Biswas K.; Richmond A.; Ko J.; Ghosh S.; Simmons M.; Rayman P.; Rini B.; Gill I.; Tannenbaum C.S.; Finke J.H. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol, 2009, 183, 5050-5058.
161. Thornton M.V.; Kudo D.; Rayman P.; Horton C.; Molto L.; Cathcart M.K.; Ng C.; Paszkiewicz-Kozik E.; Bukowski R.; Derweesh I.; Tannenbaum C.S.; Finke J.H. Degradation of NF-kappa B in T cells by gangliosides expressed on renal cell carcinomas. J Immunol, 2004, 172, 3480-3490. (Pubitemid 38337928)
162. Peguet-Navarro J.; Sportouch M.; Popa I.; Berthier O.; Schmitt D.; Portoukalian J. Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol, 2003, 170, 3488-3494. (Pubitemid 36359214)
163. Shen W.; Ladisch S. Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells. Cell Immunol, 2002, 220, 125-133. (Pubitemid 36349064)
164. Shen W.; Stone K.; Jales A.; Leitenberg D.; Ladisch S. Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol, 2008, 180, 4425-4432.
165. Caldwell S.; Heitger A.; Shen W.; Liu Y.; Taylor B.; Ladisch S. Mechanisms of ganglioside inhibition of APC function. J Immunol, 2003, 171, 1676-1683. (Pubitemid 36966449)
166. Jales A.; Falahati R.; Mari E.; Stemmy E.J.; Shen W.; Southammakosane C.; Herzog D.; Ladisch S.; Leitenberg D. Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity. Immunology, 2010.
167. Bennaceur K.; Popa I.; Chapman J.A.; Migdal C.; Peguet-Navarro J.; Touraine J.L.; Portoukalian J. Different mechanisms are involved in apoptosis induced by melanoma gangliosides on human monocyte-derived dendritic cells. Glycobiology, 2009, 19, 576-582.
168. Saraiva M.; O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol, 2010, 10, 170-181.
169. Fiorentino D.F.; Zlotnik A.; Vieira P.; Mosmann T.R.; Howard M.; Moore K.W.; O'Garra A. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol, 1991, 146, 3444-3451.
170. Macatonia S.E.; Doherty T.M.; Knight S.C.; O'Garra A. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J Immunol, 1993, 150, 3755-3765. (Pubitemid 23129757)
171. Koch F.; Stanzl U.; Jennewein P.; Janke K.; Heufler C.; Kampgen E.; Romani N.; Schuler G. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J Exp Med, 1996, 184, 741-746. (Pubitemid 26324128)
172. Jarnicki A.G.; Lysaght J.; Todryk S.; Mills K.H. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol, 2006, 177, 896-904. (Pubitemid 44036590)
173. Wu W.K.; Llewellyn O.P.; Bates D.O.; Nicholson L.B.; Dick A.D. IL-10 regulation of macrophage VEGF production is dependent on macrophage polarisation and hypoxia. Immunobiology, 2010, 215, 796-803.
174. Zeng L.; O'Connor C.; Zhang J.; Kaplan A.M.; Cohen D.A. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines. Cytokine, 2010, 49, 294-302.
175. Dace D.S.; Khan A.A.; Kelly J.; Apte R.S. Interleukin-10 promotes pathological angiogenesis by regulating macrophage response to hypoxia during development. PLoS One, 2008, 3, e3381.
176. Riboldi E.; Musso T.; Moroni E.; Urbinati C.; Bernasconi S.; Rusnati M.; Adorini L.; Presta M.; Sozzani S. Cutting edge: proangiogenic properties of alternatively activated dendritic cells. J Immunol, 2005, 175, 2788-2792. (Pubitemid 41170494)
177. Allavena P.; Piemonti L.; Longoni D.; Bernasconi S.; Stoppacciaro A.; Ruco L.; Mantovani A. IL-10 prevents the differentiation of monocytes to dendritic cells but promotes their maturation to macrophages. Eur J Immunol, 1998, 28, 359-369. (Pubitemid 28048306)
178. Longoni D.; Piemonti L.; Bernasconi S.; Mantovani A.; Allavena P. Interleukin-10 increases mannose receptor expression and endocytic activity in monocyte-derived dendritic cells. Int J Clin Lab Res, 1998, 28, 162-169.
179. Halak B.K.; Maguire H.C., Jr.; Lattime E.C. Tumor-induced interleukin-10 inhibits type 1 immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res, 1999, 59, 911-917. (Pubitemid 29086748)
180. Petersson M.; Charo J.; Salazar-Onfray F.; Noffz G.; Mohaupt M.; Qin Z.; Klein G.; Blankenstein T.; Kiessling R. Constitutive IL-10 production accounts for the high NK sensitivity, low MHC class I expression, and poor transporter associated with antigen processing (TAP)-1/2 function in the prototype NK target YAC-1. J Immunol, 1998, 161, 2099-2105. (Pubitemid 28397018)
181. Kurte M.; Lopez M.; Aguirre A.; Escobar A.; Aguillon J.C.; Charo J.; Larsen C.G.; Kiessling R.; Salazar-Onfray F. A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and Transporter associated with Antigen Processing 1/2 in human melanoma cells. J Immunol, 2004, 173, 1731-1737. (Pubitemid 38971604)
182. Groux H.; Cottrez F.; Rouleau M.; Mauze S.; Antonenko S.; Hurst S.; McNeil T.; Bigler M.; Roncarolo M.G.; Coffman R.L. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol, 1999, 162, 1723-1729. (Pubitemid 29307051)
183. Brooks D.G.; Walsh K.B.; Elsaesser H.; Oldstone M.B. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proc Natl Acad Sci U S A, 2010, 107, 3018-3023.
184. Mocellin S.; Marincola F.M.; Young H.A. Interleukin-10 and the immune response against cancer: a counterpoint. J Leukoc Biol, 2005, 78, 1043-1051. (Pubitemid 41572467)
185. Santin A.D.; Hermonat P.L.; Ravaggi A.; Bellone S.; Pecorelli S.; Roman J.J.; Parham G.P.; Cannon M.J. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J Virol, 2000, 74, 4729-4737. (Pubitemid 30237900)
186. Morel A.S.; Quaratino S.; Douek D.C.; Londei M. Split activity of interleukin-10 on antigen capture and antigen presentation by human dendritic cells: definition of a maturative step. Eur J Immunol, 1997, 27, 26-34. (Pubitemid 27046054)
187. Mocellin S.; Panelli M.; Wang E.; Rossi C.R.; Pilati P.; Nitti D.; Lise M.; Marincola F.M. IL-10 stimulatory effects on human NK cells explored by gene profile analysis. Genes Immun, 2004, 5, 621-630. (Pubitemid 40045300)
188. Cai G.; Kastelein R.A.; Hunter C.A. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Eur J Immunol, 1999, 29, 2658-2665. (Pubitemid 30098990)
189. Zheng L.M.; Ojcius D.M.; Garaud F.; Roth C.; Maxwell E.; Li Z.; Rong H.; Chen J.; Wang X.Y.; Catino J.J.; King I. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med, 1996, 184, 579-584. (Pubitemid 26324111)
190. Gerard C.M.; Bruyns C.; Delvaux A.; Baudson N.; Dargent J.L.; Goldman M.; Velu T. Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther, 1996, 7, 23-31. (Pubitemid 26119480)
191. Giovarelli M.; Musiani P.; Modesti A.; Dellabona P.; Casorati G.; Allione A.; Consalvo M.; Cavallo F.; di Pierro F.; De Giovanni C.; et al. Local release of IL-10 by transfected mouse mammary adenocarcinoma cells does not suppress but enhances antitumor reaction and elicits a strong cytotoxic lymphocyte and antibody-dependent immune memory. J Immunol, 1995, 155, 3112-3123.
192. Adris S.; Klein S.; Jasnis M.; Chuluyan E.; Ledda M.; Bravo A.; Carbone C.; Chernajovsky Y.; Podhajcer O. IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response. Gene Ther, 1999, 6, 1705-1712. (Pubitemid 29485945)
193. Huang S.; Ullrich S.E.; Bar-Eli M. Regulation of tumor growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res, 1999, 19, 697-703. (Pubitemid 29379811)
194. Berman R.M.; Suzuki T.; Tahara H.; Robbins P.D.; Narula S.K.; Lotze M.T. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol, 1996, 157, 231-238. (Pubitemid 26190552)
195. Segal B.M.; Glass D.D.; Shevach E.M. Cutting Edge: IL-10-producing CD4+ T cells mediate tumor rejection. J Immunol, 2002, 168, 1-4. (Pubitemid 34014094)
196. Fang J.; Seki T.; Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv Drug Deliv Rev, 2009, 61, 290-302.
197. Wang J.; Yi J. Cancer cell killing via ROS: to increase or decrease, that is the question. Cancer Biol Ther, 2008, 7, 1875-1884.
198. Ozben T. Oxidative stress and apoptosis: impact on cancer therapy. J Pharm Sci, 2007, 96, 2181-2196. (Pubitemid 47477879)
199. Chen Y.; Gibson S.B. Is mitochondrial generation of reactive oxygen species a trigger for autophagy? Autophagy, 2008, 4, 246-248. (Pubitemid 351231192)
200. Scherz-Shouval R.; Elazar Z. ROS, mitochondria and the regulation of autophagy. Trends Cell Biol, 2007, 17, 422-427. (Pubitemid 47499043)
201. Fiers W.; Beyaert R.; Declercq W.; Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene, 1999, 18, 7719-7730. (Pubitemid 30052757)
202. Gibson S.B. A matter of balance between life and death: targeting reactive oxygen species (ROS)-induced autophagy for cancer therapy. Autophagy, 2010, 6, 835-837.
203. Kingston D.; Schmid M.A.; Onai N.; Obata-Onai A.; Baumjohann D.; Manz M.G. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. Blood, 2009, 114, 835-843.
204. Shortman K.; Naik S.H. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol, 2007, 7, 19-30. (Pubitemid 46020824)
205. Inaba K.; Inaba M.; Romani N.; Aya H.; Deguchi M.; Ikehara S.; Muramatsu S.; Steinman R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med, 1992, 176, 1693-1702.
206. Ferrantini M.; Capone I.; Belardelli F. Dendritic cells and cytokines in immune rejection of cancer. Cytokine Growth Factor Rev, 2008, 19, 93-107. (Pubitemid 351200063)
207. Conti L.; Gessani S. GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology, 2008, 213, 859-870.
208. Tsuchiya Y.; Igarashi M.; Suzuki R.; Kumagai K. Production of colonystimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J Immunol, 1988, 141, 699-708.
209. Bronte V.; Chappell D.B.; Apolloni E.; Cabrelle A.; Wang M.; Hwu P.; Restifo N.P. Unopposed production of granulocyte-macrophage colonystimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J Immunol, 1999, 162, 5728-5737. (Pubitemid 29314923)
210. Filipazzi P.; Valenti R.; Huber V.; Pilla L.; Canese P.; Iero M.; Castelli C.; Mariani L.; Parmiani G.; Rivoltini L. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol, 2007, 25, 2546-2553. (Pubitemid 47041228)
211. Vasu C.; Dogan R.N.; Holterman M.J.; Prabhakar B.S. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulinspecific CD4+/CD25+ T cells and suppresses experimental autoimmune thyroiditis. J Immunol, 2003, 170, 5511-5522. (Pubitemid 36617839)
212. Lechner M.G.; Liebertz D.J.; Epstein A.L. Characterization of cytokineinduced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol, 2010, 185, 2273-2284.
213. Ferret-Bernard S.; Sai P.; Bach J.M. In vitro induction of inhibitory macrophage differentiation by granulocyte-macrophage colony-stimulating factor, stem cell factor and interferon-gamma from lineage phenotypesnegative c-kit-positive murine hematopoietic progenitor cells. Immunol Lett, 2004, 91, 221-227. (Pubitemid 38296382)
214. Young M.R.; Wright M.A.; Lozano Y.; Prechel M.M.; Benefield J.; Leonetti J.P.; Collins S.L.; Petruzzelli G.J. Increased recurrence and metastasis in patients whose primary head and neck squamous cell carcinomas secreted granulocyte-macrophage colony-stimulating factor and contained CD34+ natural suppressor cells. Int J Cancer, 1997, 74, 69-74. (Pubitemid 27157858)
215. Young M.R.; Wright M.A.; Lozano Y.; Matthews J.P.; Benefield J.; Prechel M.M. Mechanisms of immune suppression in patients with head and neck cancer: influence on the immune infiltrate of the cancer. Int J Cancer, 1996, 67, 333-338. (Pubitemid 26274122)
216. Sotomayor E.M.; Fu Y.X.; Lopez-Cepero M.; Herbert L.; Jimenez J.J.; Albarracin C.; Lopez D.M. Role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. II. Down-regulation of macrophage-mediated cytotoxicity by tumor-derived granulocytemacrophage colony-stimulating factor. J Immunol, 1991, 147, 2816-2823.
217. Morales J.K.; Kmieciak M.; Knutson K.L.; Bear H.D.; Manjili M.H. GMCSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloidderived suppressor cells. Breast Cancer Res Treat, 2010, 123, 39-49.
218. Curran C.S.; Evans M.D.; Bertics P.J. GM-CSF Production by Glioblastoma Cells Has a Functional Role in Eosinophil Survival, Activation, and Growth Factor Production for Enhanced Tumor Cell Proliferation. J Immunol, 2011.
219. Takeda K.; Hatakeyama K.; Tsuchiya Y.; Rikiishi H.; Kumagai K. A correlation between GM-CSF gene expression and metastases in murine tumors. Int J Cancer, 1991, 47, 413-420.
220. Clive K.S.; Tyler J.A.; Clifton G.T.; Holmes J.P.; Mittendorf E.A.; Ponniah S.; Peoples G.E. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental? Expert Rev Vaccines, 2010, 9, 519-525.
221. Sandel M.H.; Dadabayev A.R.; Menon A.G.; Morreau H.; Melief C.J.; Offringa R.; van der Burg S.H.; Janssen-van Rhijn C.M.; Ensink N.G.; Tollenaar R.A.; van de Velde C.J.; Kuppen P.J. Prognostic value of tumorinfiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res, 2005, 11, 2576-2582. (Pubitemid 40569456)
222. O'Donnell R.K.; Mick R.; Feldman M.; Hino S.; Wang Y.; Brose M.S.; Muschel R.J. Distribution of dendritic cell subtypes in primary oral squamous cell carcinoma is inconsistent with a functional response. Cancer Lett, 2007, 255, 145-152. (Pubitemid 47212612)
223. Treilleux I.; Blay J.Y.; Bendriss-Vermare N.; Ray-Coquard I.; Bachelot T.; Guastalla J.P.; Bremond A.; Goddard S.; Pin J.J.; Barthelemy-Dubois C.; Lebecque S. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res, 2004, 10, 7466-7474. (Pubitemid 39561754)
224. Gobert M.; Treilleux I.; Bendriss-Vermare N.; Bachelot T.; Goddard-Leon S.; Arfi V.; Biota C.; Doffin A.C.; Durand I.; Olive D.; Perez S.; Pasqual N.; Faure C.; Ray-Coquard I.; Puisieux A.; Caux C.; Blay J.Y.; Menetrier-Caux C. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res, 2009, 69, 2000-2009.
225. Ladanyi A.; Kiss J.; Somlai B.; Gilde K.; Fejos Z.; Mohos A.; Gaudi I.; Timar J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother, 2007, 56, 1459-1469. (Pubitemid 47024707)
226. Coventry B.J.; Morton J. CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer. Br J Cancer, 2003, 89, 533-538. (Pubitemid 37026439)
227. Iwamoto M.; Shinohara H.; Miyamoto A.; Okuzawa M.; Mabuchi H.; Nohara T.; Gon G.; Toyoda M.; Tanigawa N. Prognostic value of tumorinfiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer, 2003, 104, 92-97. (Pubitemid 36184151)
228. Cao W.; Bover L.; Cho M.; Wen X.; Hanabuchi S.; Bao M.; Rosen D.B.; Wang Y.H.; Shaw J.L.; Du Q.; Li C.; Arai N.; Yao Z.; Lanier L.L.; Liu Y.J. Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med, 2009, 206, 1603-1614.
229. Gerlini G.; Urso C.; Mariotti G.; Di Gennaro P.; Palli D.; Brandani P.; Salvadori A.; Pimpinelli N.; Reali U.M.; Borgognoni L. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. Clin Immunol, 2007, 125, 184-193. (Pubitemid 47562900)
230. Curiel T.J.; Cheng P.; Mottram P.; Alvarez X.; Moons L.; Evdemon-Hogan M.; Wei S.; Zou L.; Kryczek I.; Hoyle G.; Lackner A.; Carmeliet P.; Zou W. Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res, 2004, 64, 5535-5538. (Pubitemid 39095544)
231. Wei S.; Kryczek I.; Zou L.; Daniel B.; Cheng P.; Mottram P.; Curiel T.; Lange A.; Zou W. Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res, 2005, 65, 5020-5026. (Pubitemid 40827308)
232. Thiel A.; Kesselring R.; Pries R.; Wittkopf N.; Puzik A.; Wollenberg B. Plasmacytoid dendritic cell subpopulations in head and neck squamous cell carcinoma. Oncol Rep, 2011, 26, 615-620.
233. Schlapbach C.; Ochsenbein A.; Kaelin U.; Hassan A.S.; Hunger R.E.; Yawalkar N. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma. J Am Acad Dermatol, 2010, 62, 995-1004.
234. Mueller M.M.; Fusenig N.E. Friends or foes -bipolar effects of the tumour stroma in cancer. Nat Rev Cancer, 2004, 4, 839-849. (Pubitemid 39472951)
235. Rakoff-Nahoum S. Why cancer and inflammation? Yale J Biol Med, 2006, 79, 123-130.
236. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med, 1986, 315, 1650-1659. (Pubitemid 17052899)
237. Riss J.; Khanna C.; Koo S.; Chandramouli G.V.; Yang H.H.; Hu Y.; Kleiner D.E.; Rosenwald A.; Schaefer C.F.; Ben-Sasson S.A.; Yang L.; Powell J.; Kane D.W.; Star R.A.; Aprelikova O.; Bauer K.; Vasselli J.R.; Maranchie J.K.; Kohn K.W.; Buetow K.H.; Linehan W.M.; Weinstein J.N.; Lee M.P.; Klausner R.D.; Barrett J.C. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Cancer Res, 2006, 66, 7216-7224. (Pubitemid 44197701)
238. Erdman S.E.; Rao V.P.; Olipitz W.; Taylor C.L.; Jackson E.A.; Levkovich T.; Lee C.W.; Horwitz B.H.; Fox J.G.; Ge Z.; Poutahidis T. Unifying roles for regulatory T cells and inflammation in cancer. Int J Cancer, 2010, 126, 1651-1665.
239. Fainaru O.; Almog N.; Yung C.W.; Nakai K.; Montoya-Zavala M.; Abdollahi A.; D'Amato R.; Ingber D.E. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. Faseb J, 2010, 24, 1411-1418.
240. Norian L.A.; Rodriguez P.C.; O'Mara L.A.; Zabaleta J.; Ochoa A.C.; Cella M.; Allen P.M. Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res, 2009, 69, 3086-3094.
241. Yates S.F.; Paterson A.M.; Nolan K.F.; Cobbold S.P.; Saunders N.J.; Waldmann H.; Fairchild P.J. Induction of regulatory T cells and dominant tolerance by dendritic cells incapable of full activation. J Immunol, 2007, 179, 967-976.
242. Wang S.; Hong S.; Yang J.; Qian J.; Zhang X.; Shpall E.; Kwak L.W.; Yi Q. Optimizing immunotherapy in multiple myeloma: Restoring the function of patients' monocyte-derived dendritic cells by inhibiting p38 or activating MEK/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood, 2006, 108, 4071-4077. (Pubitemid 44913277)
243. Higham E.M.; Wittrup K.D.; Chen J. Activation of tolerogenic dendritic cells in the tumor draining lymph nodes by CD8+ T cells engineered to express CD40 ligand. J Immunol, 2010, 184, 3394-3400.
244. Shafer-Weaver K.A.; Watkins S.K.; Anderson M.J.; Draper L.J.; Malyguine A.; Alvord W.G.; Greenberg N.M.; Hurwitz A.A. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res, 2009, 69, 6256-6264.
245. Preynat-Seauve O.; Contassot E.; Schuler P.; French L.E.; Huard B. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Melanoma Res, 2007, 17, 169-176. (Pubitemid 46788101)
246. Proudfoot O.; Apostolopoulos V.; Pietersz G.A. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications. Mol Pharm, 2007, 4, 58-72.
247. Schon M.P.; Schon M. TLR7 and TLR8 as targets in cancer therapy. Oncogene, 2008, 27, 190-199.
248. Perez S.A.; von Hofe E.; Kallinteris N.L.; Gritzapis A.D.; Peoples G.E.; Papamichail M.; Baxevanis C.N. A new era in anticancer peptide vaccines. Cancer, 2010, 116, 2071-2080.
249. Murad Y.M.; Clay T.M. CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer. BioDrugs, 2009, 23, 361-375.
250. Itoh K.; Yamada A.; Mine T.; Noguchi M. Recent advances in cancer vaccines: an overview. Jpn J Clin Oncol, 2009, 39, 73-80.